Cover Image

Discrepancy in PD-L1 expression between primary and metastatic tumors in two patients with recurrent cervical cancer

Introduction: Pembrolizumab is an immunotherapy approved for use in patients with a combined positive score (CPS) greater than one with recurrent cervical cancer. In clinical practice, the CPS score is not typically analyzed in both primary and metastatic specimens. Case descriptions: Case 1A 42-yea...

Full description

Saved in:

Bibliographic Details
Main Authors:	Brittany File (Author), Anjali Hari (Author)
Format:	Book
Published:	Elsevier, 2024-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PD-1 and PD-L1 expression in rare lung tumors
by: Marton Gyulai, et al.
Published: (2023)

Meningiomas and the tumor microenvironment: expression of PD-L1 and expression of PD-L1 and interferon-gamma in the prognosis
by: Gunter Gerson, et al.

Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy
by: Brittany File, et al.
Published: (2024)

PD-1/PD-L1 Inhibitors in Cervical Cancer
by: Yuncong Liu, et al.
Published: (2019)

Immunotherapy for Recurrent and Metastatic Cervical Cancer: A Review
by: Yuke Wu, et al.
Published: (2024)

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
by: Keyu Yuan, et al.
Published: (2022)

PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
by: Jiheun Han, et al.
Published: (2017)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
by: Guilan Shi, et al.
Published: (2022)

Are PD-1 inhibitors effective for recurrent/metastatic nasopharyngeal carcinoma? Meta-analysis and systematic review
by: Le Yan, et al.
Published: (2023)

Harnessing the Systemic Immunoinflammatory Index as a Potential Predictive Tool for Recurrent or Metastatic Nasopharyngeal Carcinoma Undergoing PD-L1 Inhibitor
by: Song G, et al.
Published: (2024)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018)

Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
by: Yun Liang, et al.
Published: (2020)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
by: Yihang Qi, et al.
Published: (2021)

Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors
by: Kemal KÖSEMEHMETOĞLU, et al.
Published: (2017)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021)

Expression of PD-L1 in primary breast carcinoma and lymph node metastases
by: Alice M. Alves, et al.
Published: (2019)

PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
by: Sze‐Hwei Lee, et al.
Published: (2022)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
by: Luisa Chocarro de Erauso, et al.
Published: (2020)

Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
by: Opal L. Reddy, et al.
Published: (2017)

Cutaneous metastasis of PD-L1 positive cervical carcinoma
by: Chrissy Liu, et al.
Published: (2022)

Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors
by: Haiyue Wang, et al.
Published: (2018)

Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer
by: Shimizu K, et al.
Published: (2019)

Investigation of the PD-1/PD-L1 Expression in the Lesional Skins of Patients with Psoriasis
by: Selma Emre, et al.
Published: (2023)

Assessment of the Circulating PD-1 and PD-L1 Levels and P53 Expression as a Predictor of Relapse in Pediatric Patients with Wilms Tumor and Hypernephroma
by: Heba A. Sahyon, et al.
Published: (2024)

Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer
by: Masafumi Yasunaga, et al.
Published: (2022)

Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I)
by: Szu-Ting Yang, et al.
Published: (2024)

A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors
by: Yongming Chen, et al.
Published: (2024)

Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
by: Chen Chen, et al.
Published: (2021)

Relationship Between PD-L1, PD-1, CD8 and Clinicopathological Factors in Primary SCCs
by: Preslav Vasilev, et al.
Published: (2024)

Evaluation of the Correlation Between Vertical Facial Discrepancies and Cervical Vertebral Fusion
by: SH Emami Meibodi, et al.
Published: (2018)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
by: Qiao Liu, et al.
Published: (2022)

The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis
by: Li Wenbin, et al.
Published: (2008)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
by: Dinoop Ravindran Menon, et al.
Published: (2021)

Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer
by: Christopher B. Morse, et al.
Published: (2017)

Recurrent pembrolizumab-induced mechanical small bowel obstruction in a patient with metastatic cervical cancer
by: Sha Sha, et al.
Published: (2024)

Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer
by: Jenny‐Hoa Nguyen, et al.
Published: (2022)

The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study
by: Yu J, et al.
Published: (2019)

Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression
by: Zhen-Duo Shi, et al.
Published: (2023)

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
by: Ge Y, et al.
Published: (2022)

Profile of PD-1 and PD-L1 mRNA Expression in Peripheral Blood of Nasopharyngeal Carcinoma
by: Muhammad Al Al Azhar, et al.
Published: (2020)